As the most reliable and balanced news aggregation service on the internet, DML News App offers the following information published by WSJ.com:
Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient.
The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.
The article goes on to state the following:
Under the company’s plans, Gilead will charge a higher price for most patients in the U.S., and a lower price for the rest of the developed world where governments directly negotiate drug prices. The lower price will be extended to some U.S. government agencies, such as the Department of Veterans Affairs, but not programs such as Medicare and Medicaid that don’t directly purchase medicines, a Gilead spokesman said.
Gilead said the government will be charged $390 a dose. The cost of the shortest, most common treatment course for each patient at that price will be $2,340, or $4,290 for a longer treatment course.
Nongovernment buyers will be charged $520 a dose, or $3,120 for a patient with the shorter course and $5,720 for the longer course.
Gilead’s coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance https://t.co/eSTgu90H2X
— CNBC (@CNBC) June 29, 2020
To get more information about this article, please visit WSJ.com.